Bifidobacterium gallinarum is a distinct member of the Bifidobacterium genus, originally isolated from chicken intestines, known for its health-promoting properties.
This strain shares many benefits with other Bifidobacterium species, such as enhancing gut health, modulating the immune system, and supporting intestinal barrier integrity.
B. gallinarum's unique ability to adhere to intestinal mucus aids in mucus production and goblet cell function, contributing to overall gut health.
Recent studies highlight its potential in cancer therapy by enhancing immune responses and improving the efficacy of treatments.
Increasingly, the benefits of Bifidobacteria for gut and overall health are demonstrated in research. While specific strains are mentioned here, many of these benefits are widely attributed to Bifidobacteria as a genus.
These benefits include preventing diarrhea, improving lactose intolerance, and enhancing immune modulation. [27.]
They are effective in promoting colon regularity and alleviating constipation, while also preventing oral inflammations and dental caries. [5., 21.]
Bifidobacteria compete with pathogens, protecting against infections and inhibiting virus replication, such as Coxsackievirus B3 and rotavirus. [3., 5., 6., 7., 27.]
They show anticancer properties by enhancing immune response, inhibiting cancer cell growth, and altering gut conditions to prevent tumors. [5.]
Additionally, Bifidobacteria boost immune responses, increase beneficial antibodies, and promote regulatory T cells, contributing to anti-inflammatory effects and immune balance. [5., 10.]
They also act as psychobiotics, reducing stress, anxiety, and depression, and play a role in synthesizing gamma-Aminobutyric acid (GABA), which is particularly beneficial for individuals with autism. [2., 5., 8., 16., 18., 30., 31., 32.]
Moreover, Bifidobacteria facilitate the absorption of vitamins and minerals, promote bone density and repair, and enhance metabolic health by reducing fat accumulation and improving glucose tolerance. [1., 4., 5.,17., 22., 24., 27., 28.]
Bifidobacterium gallinarum is a distinct member of the Bifidobacterium genus, originally isolated from chicken intestines.
Unlike other bifidobacteria, B. gallinarum ferments inulin and dextrin but not starch, mannitol, or sorbitol. [33.]
One strain of B. gallinarum demonstrated acid and bile tolerance, strong adhesion to intestinal cells, and unique genomic features compared to other Bifidobacterium species, suggesting its effectiveness as a probiotic in promoting intestinal health in mammals. [20.]
Bifidobacterium gallinarum, as a member of the Bifidobacterium genus, likely shares many of the beneficial properties attributed to other Bifidobacterium species.
These benefits generally include promoting microbial diversity, supporting intestinal health, and modulating the immune system.
While specific research on B. gallinarum is limited compared to more widely studied Bifidobacterium species, its taxonomic classification suggests it may contribute to similar positive effects on gut microbiota composition, intestinal barrier function, and immune regulation.
Current research attributes the following benefits to B. gallinarum:
B. gallinarum, along with other Bifidobacterium species, possesses homologs of the FimM protein, which aids in mucus adhesion.
This interaction facilitates Bifidobacterium's beneficial effects on the host, such as enhancing mucus production, regulating goblet cell function, and maintaining intestinal barrier integrity.
These mechanisms contribute to overall gut health and can be therapeutic for conditions associated with disrupted mucus barriers.
Additional research specifically examines B. gallinarum in the context of cancer therapy. A study by Sugimura et al. (2021) demonstrated that B. gallinarum enhanced the efficacy of cancer therapeutics in tumor-bearing mice, indicating its potential role in immune modulation and anti-cancer effects. [29.]
This finding aligns with the broader understanding of Bifidobacterium species' beneficial impacts and suggests that B. gallinarum may indeed possess many of the health-promoting properties associated with its genus.
Current research suggests the use of B. gallinarum probiotic therapy as part of a comprehensive cancer care protocol.
Bifidobacterium gallinarum has been highlighted as a commensal Bifidobacterium (c-BIF) that plays a critical role in enhancing anti-tumor immunity and improving the efficacy of immune checkpoint inhibitors. [14.]
The presence of antibodies against c-BIF antigens, including those from B. gallinarum, is suggested to provide protection against malignant cells and various diseases via antigenic mimicry. [14.]
These findings indicate that B. gallinarum, like other c-BIFs, has significant potential in modulating the gut microbiota to improve cancer immunotherapy outcomes.
Bifidobacterium gallinarum levels are assessed in stool samples. Stool samples may be collected from the comfort of home.
Testing may require avoidance of certain medications and/or supplements including probiotics prior to sample collection. It is important to consult with the ordering provider for full test preparation instructions.
It is important to consult with the laboratory company used for test interpretation.
B. gallinarum levels are often reported as part of the total Bifidobacteria spp. present.
One lab company provides the following reference range for Bifidobacterium spp. levels: 6.7e7org/g [26.]
High levels of Bifidobacterium in the gut microbiome are generally associated with a healthy state and favorable metabolic outcomes.
In the setting of symptoms of dysbiosis or SIBO such as gas, bloating, and/or abdominal pain, further assessment and possible treatments should be considered.
Patients in this scenario who are using probiotics should consider stopping their probiotics.
In rare clinical settings involving either the very young or the very elderly who also have impaired intestinal barriers and/or are immunocompromised, Bifidobacterium may become invasive and cause bacteremia. [9.]
Generally, Bifidobacterium are considered to be beneficial. Low levels of Bifidobacterium have been associated with:
Therefore, maintaining a high abundance of Bifidobacterium in the gut microbiome is generally considered a favorable state, associated with better metabolic health, a lean phenotype, and a lower risk of inflammatory conditions like IBD.
Monitoring Bifidobacterium levels may have clinical significance in assessing gut health, disease risk, and potential therapeutic interventions aimed at restoring a balanced microbiome.
A healthy diet and lifestyle are foundational for microbiome health.
Click here to compare testing options and order tests to assess Bifidobacterium spp. levels.
[1.] Al-Sheraji S. H., Ismail A., Manap M. Y., Mustafa S., Yusof R. M., Hassan F. A. (2012). Hypocholesterolaemic Effect of Yoghurt Containing Bifidobacterium Pseudocatenulatum G4 or Bifidobacterium Longum BB536. Food Chem. 135, 356–361. 10.1016/j.foodchem.2012.04.120
[2.] Allen A. P., Hutch W., Borre Y. E., Kennedy P. J., Temko A., Boylan G., et al. (2016). Bifidobacterium Longum 1714 as a Translational Psychobiotic: Modulation of Stress, Electrophysiology and Neurocognition in Healthy Volunteers. Transl Psychiatry 6, e939. 10.1038/tp.2016.191
[3.] Bae E.-A., Han M. J., Song M.-J., Kim D.-H. (2002). Purification of Rotavirus Infection-Inhibitory Protein from Bifidobacterium Breve K-110. Seoul: COREE, REPUBLIQUE DE, Korean Society for Applied Microbiology.
[4.] Ballini A, Gnoni A, De Vito D, et al. Effect of probiotics on the occurrence of nutrition absorption capacities in healthy children: a randomized double-blinded placebo-controlled pilot study. European Review for Medical and Pharmacological Sciences. 2019;23(19):8645-8657. doi:https://doi.org/10.26355/eurrev_201910_19182
[5.] Chen J, Chen X, Ho CL. Recent Development of Probiotic Bifidobacterium for Treating Human Diseases. Front Bioeng Biotechnol. 2021 Dec 22;9:770248. doi: 10.3389/fbioe.2021.770248. PMID: 35004640; PMCID: PMC8727868.
[6.] Chenoll E, Rivero M, Codoñer FM, Martinez-Blanch JF, Ramón D, Genovés S, Moreno Muñoz JA. Complete Genome Sequence of Bifidobacterium longum subsp. infantis Strain CECT 7210, a Probiotic Strain Active against Rotavirus Infections. Genome Announc. 2015 Apr 2;3(2):e00105-15. doi: 10.1128/genomeA.00105-15. PMID: 25838473; PMCID: PMC4384477.
[7.] Corrêa NB, Péret Filho LA, Penna FJ, Lima FM, Nicoli JR. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol. 2005 May-Jun;39(5):385-9. doi: 10.1097/01.mcg.0000159217.47419.5b. PMID: 15815206.
[8.] Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropic. Biol Psychiatry. 2013 Nov 15;74(10):720-6. doi: 10.1016/j.biopsych.2013.05.001. Epub 2013 Jun 10. PMID: 23759244.
[9.] Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterium Infections. Bifidobacterium Bacteremia: Clinical Characteristics and a Genomic Approach To Assess Pathogenicity. J Clin Microbiol. 2017 Jul;55(7):2234-2248. doi: 10.1128/JCM.00150-17. Epub 2017 May 10. PMID: 28490487; PMCID: PMC5483926.
[10.] Fukushima Y, Kawata Y, Mizumachi K, Kurisaki J, Mitsuoka T. Effect of bifidobacteria feeding on fecal flora and production of immunoglobulins in lactating mouse. Int J Food Microbiol. 1999 Feb 18;46(3):193-7. doi: 10.1016/s0168-1605(98)00183-4. PMID: 10100899.
[11.] Gutierrez A, Pucket B, Engevik MA. Bifidobacterium and the intestinal mucus layer. Microbiome Res Rep. 2023 Sep 27;2(4):36. doi: 10.20517/mrr.2023.37. PMID: 38045921; PMCID: PMC10688832.
[12.] Hidalgo-Cantabrana C, et al. Bifidobacterium and Their Health-Promoting Effects. Bugs as Drugs. Published online February 1, 2018:73-98. doi:https://doi.org/10.1128/microbiolspec.bad-0010-2016
[13.] Hou, K., Wu, ZX., Chen, XY. et al. Microbiota in health and diseases. Sig Transduct Target Ther 7, 135 (2022). https://doi.org/10.1038/s41392-022-00974-4
[14.] Itoh K, Matsueda S. Exploring the Potential of Humoral Immune Response to Commensal Bifidobacterium as a Biomarker for Human Health, including Both Malignant and Non-Malignant Diseases: A Perspective on Detection Strategies and Future Directions. Biomedicines. 2024 Apr 4;12(4):803. doi: 10.3390/biomedicines12040803. PMID: 38672158; PMCID: PMC11048515.
[15.] Jang H. M., Jang S.-E., Han M. J., Kim D.-H. (2018). Anxiolytic-like Effect of Bifidobacterium Adolescentis IM38 in Mice with or without Immobilisation Stress. Beneficial microbes 9, 123–132. 10.3920/bm2016.0226
[16.] Jang H.-M., Lee K.-E., Kim D.-H. (2019). The Preventive and Curative Effects of Lactobacillus Reuteri NK33 and Bifidobacterium Adolescentis NK98 on Immobilization Stress-Induced Anxiety/depression and Colitis in Mice. Nutrients 11, 819. 10.3390/nu11040819
[17.] Leahy SC, Higgins DG, Fitzgerald GF, van Sinderen D. Getting better with bifidobacteria. J Appl Microbiol. 2005;98(6):1303-15. doi: 10.1111/j.1365-2672.2005.02600.x. PMID: 15916644.
[18.] Mehra A, Arora G, Sahni G, et al. Gut microbiota and Autism Spectrum Disorder: From pathogenesis to potential therapeutic perspectives. Journal of Traditional and Complementary Medicine. 2022;13(2). doi:https://doi.org/10.1016/j.jtcme.2022.03.001
[19.] Milani C, Turroni F, Duranti S, Lugli GA, Mancabelli L, Ferrario C, van Sinderen D, Ventura M. Genomics of the Genus Bifidobacterium Reveals Species-Specific Adaptation to the Glycan-Rich Gut Environment. Appl Environ Microbiol. 2015 Nov 20;82(4):980-991. doi: 10.1128/AEM.03500-15. PMID: 26590291; PMCID: PMC4751850.
[20.] Min Young Jung, Kim Y, Kim JA, Kim DH. Genomic insights and probiotic characteristics of Bifidobacterium gallinarum CACC 514 isolated from canine. Research Square (Research Square). Published online December 2, 2019. doi:https://doi.org/10.21203/rs.2.17977/v1
[21.] O'Callaghan A, van Sinderen D. Bifidobacterium and Their Role as Members of the Human Gut Microbiota. Front Microbiol. 2016 Jun 15;7:925. doi: 10.3389/fmicb.2016.00925. PMID: 27379055; PMCID: PMC4908950.
[22.] Parvaneh K, Ebrahimi M, Sabran MR, Karimi G, Hwei AN, Abdul-Majeed S, Ahmad Z, Ibrahim Z, Jamaluddin R. Probiotics (Bifidobacterium longum) Increase Bone Mass Density and Upregulate Sparc and Bmp-2 Genes in Rats with Bone Loss Resulting from Ovariectomy. Biomed Res Int. 2015;2015:897639. doi: 10.1155/2015/897639. Epub 2015 Aug 20. PMID: 26366421; PMCID: PMC4558422.
[23.] Patole SK, Rao SC, Keil AD, Nathan EA, Doherty DA, Simmer KN. Benefits of Bifidobacterium breve M-16V Supplementation in Preterm Neonates - A Retrospective Cohort Study. PLoS One. 2016 Mar 8;11(3):e0150775. doi: 10.1371/journal.pone.0150775. PMID: 26953798; PMCID: PMC4783036.
[24.] Pedret A, Valls RM, Calderón-Pérez L, Llauradó E, Companys J, Pla-Pagà L, Moragas A, Martín-Luján F, Ortega Y, Giralt M, Caimari A, Chenoll E, Genovés S, Martorell P, Codoñer FM, Ramón D, Arola L, Solà R. Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial. Int J Obes (Lond). 2019 Sep;43(9):1863-1868. doi: 10.1038/s41366-018-0220-0. Epub 2018 Sep 27. PMID: 30262813; PMCID: PMC6760601.
[25.] Pinto-Sanchez M. I., Hall G. B., Ghajar K., Nardelli A., Bolino C., Lau J. T., et al. (2017). Probiotic Bifidobacterium Longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients with Irritable Bowel Syndrome. Gastroenterology 153, 448–459. e8. 10.1053/j.gastro.2017.05.003
[26.] Rupa Health. GI-MAP + Zonulin Sample Report.pdf. Google Docs. https://drive.google.com/file/d/13LXmPBhXV2Y9paOeE5id2OM2X0V5gJ56/view
[27.] Schell MA, Karmirantzou M, Snel B, Vilanova D, Berger B, Pessi G, Zwahlen MC, Desiere F, Bork P, Delley M, Pridmore RD, Arigoni F. The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14422-7. doi: 10.1073/pnas.212527599. Epub 2002 Oct 15. Erratum in: Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9430. PMID: 12381787; PMCID: PMC137899.
[28.] Stenman LK, Waget A, Garret C, Klopp P, Burcelin R, Lahtinen S. Potential probiotic Bifidobacterium animalis ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice. Benef Microbes. 2014 Dec;5(4):437-45. doi: 10.3920/BM2014.0014. PMID: 25062610.
[29.] Sugimura N, Li Q, Chu ESH, Lau HCH, Fong W, Liu W, Liang C, Nakatsu G, Su ACY, Coker OO, Wu WKK, Chan FKL, Yu J. Lactobacillus gallinarum modulates the gut microbiota and produces anti-cancer metabolites to protect against colorectal tumourigenesis. Gut. 2021 Dec 22;71(10):2011–21. doi: 10.1136/gutjnl-2020-323951. Epub ahead of print. PMID: 34937766; PMCID: PMC9484392.
[30.] Tian P., Bastiaanssen T. F. S., Song L., Jiang B., Zhang X., Zhao J., et al. (2021). Unraveling the Microbial Mechanisms Underlying the Psychobiotic Potential of a Bifidobacterium Breve Strain. Mol. Nutr. Food Res. 65, 2000704. 10.1002/mnfr.202000704
[31.] Tian P., O'Riordan K. J., Lee Y.-K., Wang G., Zhao J., Zhang H., et al. (2020). Towards a Psychobiotic Therapy for Depression: Bifidobacterium Breve CCFM1025 Reverses Chronic Stress-Induced Depressive Symptoms and Gut Microbial Abnormalities in Mice. Neurobiol. Stress 12, 100216. 10.1016/j.ynstr.2020.100216
[32.] Wang H., Braun C., Murphy E. F., Enck P. (2019). Bifidobacterium Longum 1714 Strain Modulates Brain Activity of Healthy Volunteers during Social Stress. Am. J. Gastroenterol. 114, 1152–1162. 10.14309/ajg.0000000000000203
[33.] WATABE J, BENNO Y, T. MITSUOKA. Bifidobacterium gallinarum sp. nov.: a New Species Isolated from the Ceca of Chickens. International Journal of Systematic Bacteriology. 1983;33(2):127-132. doi:https://doi.org/10.1099/00207713-33-2-127